See the DrugPatentWatch profile for Tresiba
What influences the price of Tresiba?
The price of Tresiba (insulin degludec) is influenced by several factors, including research and development costs, manufacturing expenses, marketing, and the patent status of the drug [1]. As a branded biologic, its pricing is also set by the manufacturer, Novo Nordisk, in line with market strategies for similar advanced insulin products [2].
How does Tresiba's price compare to other insulins?
Tresiba is generally positioned as a premium, long-acting basal insulin. Its price is typically higher than older, established insulins like NPH insulin or even some other basal insulins such as Lantus (insulin glargine) [2][3]. This price difference reflects its novel formulation, extended duration of action, and potential for improved glycemic control and reduced hypoglycemia compared to older insulins [1][4].
When does Tresiba's patent protection end?
The patent landscape for Tresiba is complex and involves multiple patents covering the drug substance, formulations, and methods of use. For example, U.S. Patent No. 8,575,316, which covers insulin degludec, is listed with an expiration date of 2027, although patent challenges and extensions can alter these timelines [5]. Other related patents may expire at different times. Information on specific patent expiration dates and any related litigation can be found on resources like DrugPatentWatch.com [1][5].
Can generic or biosimilar versions of Tresiba be produced?
Once patent protections and market exclusivities expire, generic or biosimilar versions of Tresiba could potentially be developed and approved. The development of biosimilars for complex biologic drugs like insulin is a lengthy and rigorous process, requiring extensive data to demonstrate biosimilarity to the reference product [6]. The exact timing for potential market entry of biosimilars depends on the expiration of all relevant patents and regulatory approvals [1][6].
What are the patient assistance programs for Tresiba?
To help manage the cost of Tresiba, Novo Nordisk offers patient assistance programs and savings cards. These programs can reduce out-of-pocket expenses for eligible patients with commercial insurance and those who are uninsured [7]. Specific details and eligibility criteria for these programs are available through Novo Nordisk's official patient support services [7].
What is the typical out-of-pocket cost for Tresiba?
The out-of-pocket cost for Tresiba can vary significantly based on insurance coverage, pharmacy, location, and whether patient assistance programs are utilized. Without insurance or assistance, the retail price for a Tresiba pen can range from several hundred dollars. Insurance plans often have different co-pays or co-insurance amounts, and Medicare or Medicaid coverage may also impact patient costs [2][7].
Sources:
[1] DrugPatentWatch.com
[2] GoodRx, "Tresiba Prices, Coupons, and Patient Assistance Programs"
[3] Medical News Today, "Tresiba vs. Lantus: Which is best for diabetes?"
[4] Novo Nordisk, "Tresiba® (insulin degludec) Injection"
[5] United States Patent and Trademark Office, Patent Search
[6] U.S. Food & Drug Administration, "Biosimilars"
[7] Novo Nordisk, "Patient Savings Programs"